局部晚期非小细胞肺癌PD-1/PD-L1抑制剂联合放疗研究进展

Research progress of PD-1/PD-L1 inhibitor combined with radiotherapy in locally advanced non-small cell lung cancer

目的 程序性死亡受体1/程序性死亡受体配体1(PD-1/PD-L1)抑制剂联合放疗在局部晚期非小细胞肺癌(NSCLC)治疗中取得了良好的治疗效果,但最优的联合方案仍不确定,综述两者联合在局部晚期NSCLC治疗中的相关研究,以期为临床治疗提供参考。方法 以“局部晚期非小细胞肺癌、放疗、PD-1/PD-L1抑制剂”等为中文关键词,检索中国期刊全文数据库。以“locally advanced non-small cell lung cancer、radiation therapy、PD-1/PD-L1 inhibitors”等为英文关键对Pubmed和Web of Science数据库进行检索,共检索到中文文献58篇,英文文献328篇。纳入标准:(1)局部晚期NSCLC的流行病学;(2)PD-1/PD-LI抑制剂联合放疗在局部晚期NSCLC治疗中的研究进展。共纳入文献29篇。结果 不同PD-1/PD-L1抑制剂联合不同放疗方案治疗,使局部晚期NSCLC的生存期延长,但两者联合的顺序及放疗剂量、分割方式的最优选择仍然存在争议。结论 PD-1/PD-LI抑制剂联合放疗在局部晚期NSCLC治疗中取得了良好的治疗效果,但如何根据不同的患者选择最优联合方案仍需要进一步探讨。

Objective Programmed death receptor-1/programmed death receptor ligand-1(PD-1/PD-L1) inhibitor combined with radiotherapy has achieved good therapeutic effect in the treatment of locally advanced non-small-cell lung cancer(NSCLC),but the optimal combination is still uncertain.This paper mainly reviews the related studies on the combination of the two in the treatment of locally advanced NSCLC,in order to provide reference for clinical treatment.Methods The "locally advanced non-small cell lung cancer, radiation therapy, PD-1/PD-L1 inhibitors" were selected as the keywords from Chinese National Knowledge Infrastructure(CNKI),Pubmed and Web of Science databases, 58 Chinese literatures and 328 English literatures were retrieved.Inclusion criteria:(1) epidemiology of locally advanced non-small cell lung cancer;(2) research progress of PD-1/PD-Li inhibitor combined with radiotherapy in the treatment of locally advanced NSCLC.A total of 29 literatures were included.Results Different PD-1/PD-L1 inhibitors combined with different radiotherapy regimens prolong the survival of locally advanced NSCLC,but the combination sequence and optimal selection of radiotherapy dose and segmentation remain controversial.Conclusion The combination of PD-1/PD-L1 inhibitor and radiotherapy has achieved a good therapeutic effect in the treatment of locally advanced NSCLC.However, further research is needed on how to select the optimal combination scheme for different patients.